{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:03:43Z","timestamp":1784901823957,"version":"3.55.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"City of Dublin Skin"},{"name":"Cancer Hospital Charity"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bimekizumab is a humanized monoclonal antibody to interleukins-17A and -17F, licensed in 2023 for the treatment of moderate to severe hidradenitis suppurativa (HS). This retrospective case series discusses 15 patients who were treated with bimekizumab for HS. Of the total, 74% were female. The mean age of the patients was 42\u2005years; 87% had Hurley stage III HS and the mean baseline International Hidradenitis Suppurativa Severity Score System score was 20.13. All were biologic experienced and 11\/15 were taking concomitant medications for the treatment of HS. At 16 weeks, as calculated by HS Clinical Response or HS Physician Global Assessment, 10\/15 (67%) patients responded to bimekizumab. The mean Dermatology Life Quality Index fell by nine points. One patient experienced secondary failure at 9\u2005months. Response rates in this group at week 16 were higher than those seen in phase III clinical trials, despite previous biologic exposure in all patients. While concomitant HS medication may play a role in this higher response rate, bimekizumab is an important treatment option for moderate to severe HS.<\/jats:p>","DOI":"10.1093\/ced\/llag140","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:36:39Z","timestamp":1774956999000},"page":"1478-1481","source":"Crossref","is-referenced-by-count":1,"title":["Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: a real-world, single-centre case series"],"prefix":"10.1093","volume":"51","author":[{"given":"Emily K","family":"Pender","sequence":"first","affiliation":[{"name":"Charles Centre, Department of Dermatology, St Vincent\u2019s University Hospital , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7087-1070","authenticated-orcid":false,"given":"Emma","family":"Carroll","sequence":"additional","affiliation":[{"name":"Charles Centre, Department of Dermatology, St Vincent\u2019s University Hospital , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Alexandra","family":"Visan","sequence":"additional","affiliation":[{"name":"Charles Centre, Department of Dermatology, St Vincent\u2019s University Hospital , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Hughes","sequence":"additional","affiliation":[{"name":"Charles Centre, Department of Dermatology, St Vincent\u2019s University Hospital , Dublin ,","place":["Ireland"]},{"name":"Charles Institute of Dermatology, School of Medicine, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Charles Centre, Department of Dermatology, St Vincent\u2019s University Hospital , Dublin ,","place":["Ireland"]},{"name":"Charles Institute of Dermatology, School of Medicine, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2026072409171789900_llag140-B1","article-title":"Annex 1: Summary of Product Characteristics","author":"Bimzelx","journal-title":"European Medicines Agency"},{"key":"2026072409171789900_llag140-B2","first-page":"2504","volume-title":"Lancet","author":"Kimball","year":"2024"},{"key":"2026072409171789900_llag140-B3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072409171789900_llag140-B4","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/ajd.14339","article-title":"Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: an ambispective observational study","volume":"65","author":"Mansilla-Polo","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026072409171789900_llag140-B5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ced\/llad229","article-title":"Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment","volume":"48","author":"Molinelli","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2026072409171789900_llag140-B6","doi-asserted-by":"crossref","first-page":"104491","DOI":"10.1016\/j.ad.2025.104491","article-title":"Real world evidence of secukinumab and bimekizumab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"117","author":"Haselgruber","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"2026072409171789900_llag140-B7","doi-asserted-by":"crossref","first-page":"e823","DOI":"10.1111\/jdv.19921","article-title":"Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: lessons and pitfalls in a \u00adreal-world setting","volume":"38","author":"Urena-Paniego","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072409171789900_llag140-B8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2026072409171789900_llag140-B9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/bjd\/ljae098","article-title":"Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials","volume":"190","author":"Zouboulis","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag140\/67696242\/llag140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1478\/67696242\/llag140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1478\/67696242\/llag140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:25Z","timestamp":1784899045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1478\/8566506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,23]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag140","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,23]]}}}